Leiomyosarcoma medical therapy: Difference between revisions
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) |
||
| Line 11: | Line 11: | ||
==Radiation Therapy== | ==Radiation Therapy== | ||
'''Radiation therapy:''' Radiotherapy may be a useful adjunct to improve local control or where a cancer is inoperable due to the specific location or possible progression of the malignancy.It can be used postoperative to help treat known or possible residual disease.Radiation therapy can also be used as a palliative care in cases where extensive metastasis has already occurred.<ref name="pmid18378136">Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18378136 Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).] ''Eur J Cancer'' 44 (6):808-18. [http://dx.doi.org/10.1016/j.ejca.2008.01.019 DOI:10.1016/j.ejca.2008.01.019] PMID: [https://pubmed.gov/18378136 18378136]</ref> | |||
* Adjuvant pelvic radiotherapy has been shown by some to improve disease-free survival. <ref name="HarryNarayansingh2007">{{cite journal|last1=Harry|first1=Vanessa N|last2=Narayansingh|first2=Gordon V|last3=Parkin|first3=David E|title=Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls|journal=The Obstetrician & Gynaecologist|volume=9|issue=2|year=2007|pages=88–94|issn=14672561|doi=10.1576/toag.9.2.088.27309}}</ref> | |||
* Studies had shown that there is a 38% disease-free survival rate in women receiving adjuvant radiotherapy compared with 18% in women receiving surgery alone.<ref name="HarryNarayansingh20072">{{cite journal|last1=Harry|first1=Vanessa N|last2=Narayansingh|first2=Gordon V|last3=Parkin|first3=David E|title=Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls|journal=The Obstetrician & Gynaecologist|volume=9|issue=2|year=2007|pages=88–94|issn=14672561|doi=10.1576/toag.9.2.088.27309}}</ref> | |||
==Palliative treatment== | ==Palliative treatment== | ||
Revision as of 14:16, 5 March 2019
|
Leiomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leiomyosarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Leiomyosarcoma medical therapy |
|
Risk calculators and risk factors for Leiomyosarcoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Rekha, M.D.
Overview
Leiomyosarcoma treatment consist of multidisciplinary approach and is best carried out at the specialized hospital setting.Patients with leiomyosarcoma have many treatment options. The selection depends on the stage of the tumor. The options are surgery, radiation therapy, chemotherapy, or a combination of these methods. Before treatment starts, ask your health care team about possible side effects and how treatment may change your normal activities. Because cancer treatments often damage healthy cells and tissues, side effects are common. Side effects may not be the same for each person, and they may change from one treatment session to the next.Non surgical treatment options have shown only limited benefit in the treatment of the Leiomyosarcoma and are generally considered to be less responsive of chemotherapy and radiotherapy.It has generally noted that only 40% cases responds to the chemotherapeutic regimens.
Chemotherapy
- Chemotherapy: For individuals, particularly those who have locally advanced, metastatic, or recurrent disease, chemotherapy may also be recommended, possibly in combination with surgical procedures and/or radiation.The treatment is to use drugs to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Usual drugs include ifosfamide and doxorubicin (Adriamycin).[1][2] Surgical resection of localized disease is a well‐established therapeutic strategy 9. In the event tumors have metastasized, hormonal therapy 10 and cytotoxic chemotherapeutic agents such as gemcitabine 11, docetaxel 12, 13, anthracyclines 14, 15, ifosfamide 16, temozolomide 17, trabectedin 18, 19, eribulin 20, 21, and many other cytotoxic agents provide modest antitumor activity 22. In contrast, novel targeted therapeutic agents have not widely used for the treatment of advanced LMS.
Radiation Therapy
Radiation therapy: Radiotherapy may be a useful adjunct to improve local control or where a cancer is inoperable due to the specific location or possible progression of the malignancy.It can be used postoperative to help treat known or possible residual disease.Radiation therapy can also be used as a palliative care in cases where extensive metastasis has already occurred.[3]
- Adjuvant pelvic radiotherapy has been shown by some to improve disease-free survival. [4]
- Studies had shown that there is a 38% disease-free survival rate in women receiving adjuvant radiotherapy compared with 18% in women receiving surgery alone.[5]
Palliative treatment
- Palliative treatment: This treatment is used for the patients whose cancer has spread. It may improve the patient's quality of life by controlling the symptoms and complications of this disease.
References
- ↑ Blay JY (2018) Getting up-to-date in the management of soft tissue sarcoma. Future Oncol 14 (10s):3-13. DOI:10.2217/fon-2018-0074 PMID: 29768050
- ↑ (1969) New antiviral drug. Nature 222 (5190):218. PMID: 5778386
- ↑ Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S et al. (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44 (6):808-18. DOI:10.1016/j.ejca.2008.01.019 PMID: 18378136
- ↑ Harry, Vanessa N; Narayansingh, Gordon V; Parkin, David E (2007). "Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls". The Obstetrician & Gynaecologist. 9 (2): 88–94. doi:10.1576/toag.9.2.088.27309. ISSN 1467-2561.
- ↑ Harry, Vanessa N; Narayansingh, Gordon V; Parkin, David E (2007). "Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls". The Obstetrician & Gynaecologist. 9 (2): 88–94. doi:10.1576/toag.9.2.088.27309. ISSN 1467-2561.